Currently, HDAC6 inhibitor ACY-1215 has been reported under clinical trials for different cancer therapy either monotherapy or in combination with other drugs, such as metastatic breast cancer and myeloid leukemia, which suggested targeting HDAC6 may become promising strategy in cancer therapy (12, 24). The gene discussed is HDAC6; the disease is myeloid leukemia.